Top-Rated StocksTop-Rated Merus Stock Price, News & Analysis (NASDAQ:MRUS) $23.93 -0.83 (-3.35%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$23.76▼$24.9250-Day Range$20.06▼$25.1352-Week Range$12.44▼$27.70Volume344,335 shsAverage Volume383,214 shsMarket Capitalization$1.38 billionP/E RatioN/ADividend YieldN/APrice Target$44.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Merus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.4% Upside$44.60 Price TargetShort InterestBearish11.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.14Based on 8 Articles This WeekInsider TradingSelling Shares$14,133 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.61) to ($3.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 starsMedical Sector803rd out of 932 stocksPharmaceutical Preparations Industry377th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingMerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.60, Merus has a forecasted upside of 86.4% from its current price of $23.93.Amount of Analyst CoverageMerus has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.36% of the outstanding shares of Merus have been sold short.Short Interest Ratio / Days to CoverMerus has a short interest ratio ("days to cover") of 19.1, which indicates bearish sentiment.Change versus previous monthShort interest in Merus has recently increased by 0.31%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMerus does not currently pay a dividend.Dividend GrowthMerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRUS. Previous Next 1.6 News and Social Media Coverage News SentimentMerus has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Merus this week, compared to 2 articles on an average week.MarketBeat Follows9 people have added Merus to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,133.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Merus is held by insiders.Percentage Held by Institutions90.68% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Merus are expected to decrease in the coming year, from ($2.61) to ($3.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merus is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merus is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerus has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Merus Stock (NASDAQ:MRUS)Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Read More MRUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRUS Stock News HeadlinesDecember 5, 2023 | finance.yahoo.comMerus N.V. (MRUS) Moves to Buy: Rationale Behind the UpgradeDecember 5, 2023 | americanbankingnews.comMerus' (MRUS) "Buy" Rating Reaffirmed at Needham & Company LLCDecember 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 4, 2023 | markets.businessinsider.comMerus: Buy Rating Justified by Clinical Progress and Market PotentialDecember 4, 2023 | msn.comMerus falls after updated data for lung cancer therapyDecember 3, 2023 | finanznachrichten.deMerus N.V.: Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023December 3, 2023 | finance.yahoo.comMerus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023November 29, 2023 | markets.businessinsider.comBuy Rating on Merus Stock Backed by Strong Clinical Data and Strategic Development MovesDecember 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 28, 2023 | markets.businessinsider.comMerus’s MCLA-129: Promising Early Results and Strategic Positioning Underpin Buy RatingNovember 26, 2023 | finance.yahoo.comMerus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023November 23, 2023 | finance.yahoo.comWall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?November 7, 2023 | finance.yahoo.comWall Street Analysts Think Merus N.V. (MRUS) Could Surge 83.26%: Read This Before Placing a BetNovember 6, 2023 | markets.businessinsider.comPositive Outlook for Merus: Stability, Promising Pipeline, and Robust Financial Health Reinforce Buy RatingNovember 5, 2023 | morningstar.comMerus NV MRUSNovember 4, 2023 | markets.businessinsider.comPromising Clinical Trials and Future Catalysts Strengthen Buy Rating for MerusNovember 2, 2023 | finanznachrichten.deMerus N.V.: Merus Announces Financial Results for the Third Quarter 2023 and Provides Business UpdateNovember 2, 2023 | finance.yahoo.comMerus Announces Financial Results for the Third Quarter 2023 and Provides Business UpdateOctober 23, 2023 | stockhouse.comMerus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ CancerOctober 23, 2023 | finance.yahoo.comMerus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ CancerOctober 19, 2023 | markets.businessinsider.comPositive Pipeline Developments and Upcoming Trials Bolster Merus Stock: An In-depth Analysis of Berens’ Buy Rating RecommendationOctober 17, 2023 | finance.yahoo.comMerus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?October 16, 2023 | markets.businessinsider.comPromising Outcomes for Cetuximab and Petosemtamab in HNSCC Treatment: An Analysis of the INTERLINK-1 ESMO Data and Future ProspectsOctober 15, 2023 | finance.yahoo.comMerus Announces Business Update Conference CallOctober 6, 2023 | finanznachrichten.deMerus N.V.: Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023October 6, 2023 | finance.yahoo.comMerus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023October 5, 2023 | finance.yahoo.comWhile Merus (NASDAQ:MRUS) shareholders have made 67% in 3 years, increasing losses might now be front of mind as stock sheds 12% this weekSee More Headlines Receive MRUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRUS CUSIPN/A CIK1651311 Webwww.merus.nl Phone(130) 253-8800FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$44.60 High Stock Price Target$49.00 Low Stock Price Target$35.00 Potential Upside/Downside+86.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,190,000.00 Net Margins-387.00% Pretax Margin-381.43% Return on Equity-63.39% Return on Assets-45.01% Debt Debt-to-Equity RatioN/A Current Ratio6.29 Quick Ratio6.29 Sales & Book Value Annual Sales$41.59 million Price / Sales33.22 Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book4.48Miscellaneous Outstanding Shares57,730,000Free Float55,250,000Market Cap$1.38 billion OptionableNot Optionable Beta0.82 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Sven Ante Lundberg M.D. (Age 60)CEO, President & Executive Director Comp: $953.06kMr. Gregory D. Perry (Age 63)CFO & Principal Financial Officer Comp: $63.76kMr. Peter B. Silverman J.D. (Age 45)EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal Comp: $601.19kDr. Hui Liu Ph.D. (Age 56)Chief Business Officer, Executive VP & Head of Merus U.S. Comp: $597.7kDr. Andrew Joe M.D. (Age 57)Chief Medical Officer & Senior VP Comp: $692.74kDr. Hennie HoogenboomCo-Founder and Scientific AdvisorHarry ShumanChief Accounting OfficerMr. Cornelis Adriaan de Kruif Ph.D. (Age 58)CTO & Executive VP Comp: $348.73kDr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VPMs. Jillian ConnellVP of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsAmneal PharmaceuticalsNYSE:AMRXPacira BioSciencesNASDAQ:PCRXMaravai LifeSciencesNASDAQ:MRVIAbCellera BiologicsNASDAQ:ABCLPOINT Biopharma GlobalNASDAQ:PNTView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPBought 86,512 shares on 12/7/2023Ownership: 0.291%Wellington Management Group LLPBought 60,135 shares on 12/1/2023Ownership: 4.738%Harry ShumanSold 575 sharesTotal: $14,133.50 ($24.58/share)Carmignac GestionBought 40,008 shares on 11/29/2023Ownership: 0.787%Polar Capital Holdings PlcSold 250,000 shares on 11/22/2023Ownership: 0.866%View All Insider TransactionsView All Institutional Transactions MRUS Stock Analysis - Frequently Asked Questions Should I buy or sell Merus stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRUS shares. View MRUS analyst ratings or view top-rated stocks. What is Merus' stock price target for 2024? 11 Wall Street research analysts have issued 12 month target prices for Merus' shares. Their MRUS share price targets range from $35.00 to $49.00. On average, they predict the company's stock price to reach $44.60 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price. View analysts price targets for MRUS or view top-rated stocks among Wall Street analysts. How have MRUS shares performed in 2023? Merus' stock was trading at $15.47 at the beginning of 2023. Since then, MRUS stock has increased by 54.7% and is now trading at $23.93. View the best growth stocks for 2023 here. When is Merus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our MRUS earnings forecast. How were Merus' earnings last quarter? Merus (NASDAQ:MRUS) posted its quarterly earnings data on Thursday, November, 2nd. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.30. The biotechnology company had revenue of $11.03 million for the quarter, compared to analysts' expectations of $10.96 million. Merus had a negative net margin of 387.00% and a negative trailing twelve-month return on equity of 63.39%. What ETFs hold Merus' stock? ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Merus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include Pfizer (PFE), Micron Technology (MU), OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Five Prime Therapeutics (FPRX) and Fulcrum Therapeutics (FULC). When did Merus IPO? (MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers. Who are Merus' major shareholders? Merus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (6.72%), Federated Hermes Inc. (5.00%), Wellington Management Group LLP (4.74%), RTW Investments LP (3.46%), Braidwell LP (3.29%) and Lynx1 Capital Management LP (1.99%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg. View institutional ownership trends. How do I buy shares of Merus? Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:MRUS) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.